Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Inclusion Criteria: * Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study according to the protocol; * At least 18 years of age at the time of signing the ICF; * Body mass index met the requirements; * HBeAg negative at screening; * HBsAg or HBV DNA positive for at least 6 months; * Meet relevant requirements for NAs treatment; * 100 IU/mL \< HBsAg ≤ 3000 IU/mL, HBV DNA \< 100 IU/mL and liver function indicators meet the requirements; * Effective contraception as required. Exclusion Criteria: * Clinically significant abnormalities other than a history of chronic HBV infection; * Concomitant clinically significant other liver diseases; * Previous/current manifestations of hepatic decompensation; * Significant hepatic fibrosis or cirrhosis; * Presence of protocol-specified laboratory abnormalities; * History of malignancy or ongoing assessment of possible malignancy; * Those allergic to AHB-137 or its components; * Participants with recent major trauma or major surgery, or planning surgery; * Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study; * Prior/current use of prohibited medications; * Inappropriate for participation in this trial as judged by the investigator.